Introduction:

Progress in the diagnostic-therapeutic approach in lung cancer has been achieved thanks to the knowledge of tumor heterogeneity and optimization in molecular analysis.

Material and methods:

Cases of patients with lung cancer from 2015 to 2018 were reviewed, recording sociodemographic, clinical, molecular and result variables of T790M. The results were expressed in measures of central tendency and Kaplan-Meier curves were constructed.

Results:

Of the total of patients with lung cancer in INER, it was found that 93.74% (n = 704) were non-small cell lung cancer, 86% (n = 606) were adenocarcinomas and 42.63% (n = 191) had sensitive mutated EGFR. A total of 30 samples were sent to T790M determination, being positive at 50%. The majority were female, never smokers. The median progression-free survival was 13 months.

Conclusion:

In this study we found a resistance frequency acquired in T790M higher than in other countries. These allow to know the importance of the determination of T790M in patients who receive inhibitors of tyrosine kinase in front of the progression offering a second line in time of impact on the prognosis.